Cancer incidence is increasingly seen in younger individuals. Molecular distinctions between young and elderly patients at onset are understudied. This study used public databases to explore genomic, transcriptomic, and immune-related features across age groups in cervical cancer. Additionally, it aims to create a prognostic model applicable across diverse age cohorts, enabling precise patient stratification, and personalized therapies. Gene mutations, expression data, and clinicopathological information were obtained from 317 cervical cancer patients. These patients were divided into a young group and an old group based on the median age of onset. The characteristics of differential gene mutation, gene expression, and immune cells analysis were analyzed by R software. Finally, the prognostic model was constructed by univariate Cox, least absolute shrinkage and selection operator, and multivariate Cox regression analyses of angiogenic and immune gene sets. Its validity was further confirmed using an additional 300 cervical squamous cell carcinoma and endocervical adenocarcinoma tissues. Cervical cancer patients at elderly onset age exhibit a significantly higher frequency of NOTCH1 and TP53 driver mutations compared to young patients, along with a notably higher tumor mutational burden. However, there were no significant differences between the 2 groups in terms of genomic instability and age-related mutational signatures. Differential gene expression analysis revealed that the young group significantly upregulated interferon-alpha and gamma responses and exhibited significantly higher activity in multiple metabolic pathways. Immune microenvironment analysis indicated enrichment of dendritic cells and natural killer cells in the young group, while transforming growth factor-β signature was enriched in the elderly group, indicating a higher degree of immune exclusion. A multigene prognostic model based on angiogenesis and T cell immune gene sets showed excellent prognostic performance independent of clinical factors such as age. High-risk groups identified by the model exhibit significant activation of tumor-promoting processes, such as metastasis and angiogenesis. Our study reveals distinct patterns in cancer-driving mechanisms, biological processes, and immune system status between young and elderly patients at onset with cervical cancer. These findings shed light on the age-specific underlying mechanisms of carcinogenesis. Furthermore, an independent molecular prognostic model is constructed to provide valuable references for patient stratification and the development of potential drug targets.

Background: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) often coexists with anxiety and depression. This study assessed whether adding psychological intervention (PI) to standard pharmacotherapy improves patient outcomes. Methods: One hundred sixty eight adult patients diagnosed with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) were recruited for this study. They were randomly divided into control and PI groups. All patients in both groups received a 30-day standard prostatitis pharmacotherapy regimen with levofloxacin and tamsulosin. Additionally, the 84 patients in the PI group received PIs, unlike those in the control group. The self-rating depression scale and self-rating anxiety scale were employed to assess the psychological symptoms before and 3 months after the therapeutic treatments. Results: Following treatment, the PI group exhibited significantly better recovery from symptoms of anxiety, depression, and prostatitis compared to the control group. Multiple linear regression analysis revealed that patients with longer disease durations had higher self-rating anxiety scale, self-rating depression scale, and National Institutes of Health-Chronic Prostatitis Symptom Index Scale scores. The study demonstrated that PI has positive early effects on patients with CP/CPPS. However, its efficacy decreases as the duration of the disease progresses. Conclusion: The combination of PI and conventional antibiotics is effective for CP/CPPS patients with longer disease course and more severe symptoms. Early PI is recommended to achieve better therapeutic results.